Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.38 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.35 |
| ▸ | SRC | P12931 | 1/20 | 0.35 |
| ▸ | CCR8 | P51685 | 1/20 | 0.34 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.34 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.34 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.34 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.34 |
| ▸ | CDC7 | O00311 | 1/20 | 0.34 |
| ▸ | PARP1 | P09874 | 5/20 | 0.34 |
| ▸ | KDR | P35968 | 1/20 | 0.34 |
| ▸ | PRKD1 | Q15139 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | FKBP5 | Q13451 | 1/20 | 0.32 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.32 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.32 |
| ▸ | PRKCG | P05129 | 1/20 | 0.32 |
| ▸ | PRKCB | P05771 | 1/20 | 0.32 |
| ▸ | PRKCA | P17252 | 1/20 | 0.32 |
| ▸ | PRKCH | P24723 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL706419 | 0.72 | — | — | |
| SCHEMBL293154 | 0.71 | PARP1 (0.40) | CCR8PARP1KMT2AKDM4EALDH1A1 | |
| SCHEMBL19032017 | 0.69 | PARP1 (0.39) | CCR8PARP1KMT2AKDM4EALDH1A1 | |
| SCHEMBL30667285 | 0.68 | DYRK1A (0.39) | MAP2K1CCR8PARP1KMT2AKDM4E | |
| SCHEMBL6321531 | 0.67 | FKBP5 (0.34) | GRIA1GRIA2GRIA3GRIA4FKBP5 | |
| SCHEMBL31747859 | 0.65 | CCR8 (0.32) | CCR8PARP1KMT2A | |
| SCHEMBL9488322 | 0.65 | DAO (0.37) | CDC7PARP1KDRKDM4EALDH1A1 | |
| SCHEMBL7156772 | 0.64 | MAP2K1 (0.52) | OR51E2MAP2K1GRIA1GRIA2GRIA3 | |
| SCHEMBL7103933 | 0.63 | GRIA1 (0.56) | OR51E2MAP2K1GRIA1GRIA2GRIA3 | |
| SCHEMBL18561333 | 0.63 | UHRF1 (0.36) | OR51E2KMT2AKDM4EALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2013126156-A1 | NITRIC OXIDE DONATING SELECTIVE GLUCOCORTICOID RECEPTOR AGONIST COMPOUNDS AND OPHTHALMIC COMPOSITIONS | BAUSCH & LOMB INCORPORATED (US) | 2013-08-29 | — | — | WO | claimed |
| EP-2203160-A1 | PHARMACOLOGICAL ADJUNCTIVE TREATMENT ASSOCIATED WITH GLAUCOMA FILTRATION SURGERY | Bausch & Lomb Incorporated (US) | 2010-07-07 | — | — | EP | claimed |
| JP-2010502723-A | — | — | 2010-01-28 | — | — | JP | claimed |
| JP-2010502635-A | — | — | 2010-01-28 | — | — | JP | claimed |
| EP-2121670-A2 | SYNTHESIS OF SELECTED STEREOISOMERS OF CERTAIN SUBSTITUTED ALCOHOLS | Bausch & Lomb Incorporated (US) | 2009-11-25 | — | — | EP | claimed |
| US-7579469-B2 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2009-08-25 | — | — | US | claimed |
| EP-2086921-A2 | SYNTHESIS OF SELECTED STEREOISOMERS OF CERTAIN SUBSTITUTED ALCOHOLS | Bausch & Lomb Incorporated (US) | 2009-08-12 | — | — | EP | claimed |
| EP-2061444-A2 | COMPOSITIONS AND METHODS FOR TREATING, CONTROLLING, REDUCING, AMELIORATING, OR PREVENTING ALLERGY | Bausch & Lomb Incorporated (US) | 2009-05-27 | — | — | EP | claimed |
| EP-2056799-A2 | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING GLAUCOMA OR PROGRESSION THEREOF | Bausch & Lomb Incorporated (US) | 2009-05-13 | — | — | EP | claimed |
| EP-2051736-A2 | COMPOSITIONS COMPRISING A DISSOCIATED GLUCOCORTICOID RECEPTOR AGONIST AND AN IMMUNOSUPPRESSIVE AGENT FOR TREATING DRY EYE | Bausch & Lomb Incorporated (US) | 2009-04-29 | — | — | EP | claimed |
| WO-2008021729-A2 | COMPOSITIONS AND METHODS FOR TREATING, REDUCING, AMELIORATING, OR ALLEVIATING POSTERIOR-SEGMENT OPHTHALMIC DISEASES | BAUSCH & LOMB INCORPORATED (US) | 2008-02-21 | — | — | WO | claimed |
| WO-2008021728-A2 | TREATING INFECTIONS AND SEQUELAE THEREOF WITH COMBINED DISSOCIATED' GLUCOCORTICOID RECEPTOR AGONISTS AND ANTI-INFECTIVE AGENTS | BAUSCH & LOMB INCORPORATED (US) | 2008-02-21 | — | — | WO | claimed |
| US-20080031884-A1 | COMPOSITIONS AND METHODS FOR TREATING, REDUCING, AMELIORATING, OR ALLEVIATING POSTERIOR-SEGMENT OPHTHALMIC DISEASES | BAUSCH HEALTH US, LLC | 2008-02-07 | — | — | US | claimed |
| US-20080033008-A1 | COMPOSITIONS AND METHODS FOR TREATING, CONTROLLING, REDUCING, OR AMELIORATING INFECTIONS AND SEQUELAE THEREOF | BAUSCH HEALTH COMPANIES INC. (CA) | 2008-02-07 | — | — | US | claimed |
| US-20080009437-A1 | Pharmaceutical Compositions and Method for Treating Dry Eye | SALIX PHARMACEUTICALS, INC. | 2008-01-10 | — | — | US | claimed |
| WO-2008005686-A2 | COMPOSITIONS COMPRISING A DISSOCIATED GLUCOCORTICOID RECEPTOR AGONIST AND AN IMMUNOSUPPRESSIVE AGENT FOR TREATING DRY EYE | BAUSCH & LOMB INCORPORATED (US) | 2008-01-10 | — | — | WO | claimed |
| WO-2007115820-A1 | CHROMEN-2-ONE DERIVATIVES | NOVARTIS AG (CH) | 2007-10-18 | — | — | WO | claimed |
| EP-1583745-A1 | 1-PROPANOL AND 1-PROPYLAMINE DERIVATIVES AND THEIR USE AS GLUCOCORTICOID LIGANDS | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2005-10-12 | — | — | EP | claimed |
| US-20040162321-A1 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2004-08-19 | — | — | US | claimed |
| WO-2004063163-A1 | 1-PROPANOL AND 1-PROPYLAMINE DERIVATIVES AND THEIR USE AS GLUCOCORTICOID LIGANDS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2004-07-29 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080033008-A1 | COMPOSITIONS AND METHODS FOR TREATING, CONTROLLING, REDUCING, OR AMELIORATING INFECTIONS AND SEQUELAE THEREOF | NR3C1, GNRHR, GSR | OR51E2 2987/4885MAP2K1 3121/4885SRC 887/4885 |
| US-20080031884-A1 | COMPOSITIONS AND METHODS FOR TREATING, REDUCING, AMELIORATING, OR ALLEVIATING POSTERIOR-SEGMENT OPHTHALMIC DISEASES | PTGIR, GCGR, NR3C1 | OR51E2 2690/4885MAP2K1 1708/4885SRC 2248/4885 |
| US-20080009437-A1 | Pharmaceutical Compositions and Method for Treating Dry Eye | NR3C1, GCGR, GPBAR1 | OR51E2 1030/4885MAP2K1 1520/4885SRC 769/4885 |
| US-20040162321-A1 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof | NR3C1, NR3C2, MC2R | OR51E2 2755/4885MAP2K1 3202/4885SRC 807/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.